Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Plinabulin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 2/20 | 0.70 |
| ▸ | TUBB known ✓ | P07437 | 2/20 | 0.70 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 2/20 | 0.70 |
| ▸ | TUBA1B known ✓ | P68363 | 2/20 | 0.70 |
| ▸ | TUBA4A known ✓ | P68366 | 2/20 | 0.70 |
| ▸ | TUBB4B known ✓ | P68371 | 2/20 | 0.70 |
| ▸ | TUBB3 known ✓ | Q13509 | 2/20 | 0.70 |
| ▸ | TUBB2A known ✓ | Q13885 | 2/20 | 0.70 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 2/20 | 0.70 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 2/20 | 0.70 |
| ▸ | TUBA1A known ✓ | Q71U36 | 2/20 | 0.70 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 2/20 | 0.70 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 2/20 | 0.70 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 2/20 | 0.70 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Plinabulin SCHEMBL29033820 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL29216847 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL28720406 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL21050030 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL17979608 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL31329443 | 0.99 | CYP1A2 (0.97) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL30522117 | 0.99 | CYP1A2 (0.97) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL31329439 | 0.99 | CYP1A2 (0.97) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL19858952 | 0.99 | CYP1A2 (0.97) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL31329436 | 0.94 | CYP1A2 (0.88) | CYP1A2CYP2C9CYP2C19RAF1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 947 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102168-A1 | FIRST-LINE COMBINATION THERAPY WITH PLINABULIN FOR TREATING SMALL CELL LUNG CANCER | BEYONDSPRING PHARMACEUTICALS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260130851-A1 | PLINABULIN MICELLE COMPOSITION AND PREPARATION METHOD THEREFOR | BEYONDSPRING PHARMACEUTICALS INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4719416-A1 | ONCOLOGY COMBINATION THERAPY AND METHODS OF USE | Beyondspring Pharmaceuticals, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260048022-A1 | ENDOTHELIAL DAMAGE AND NANOPARTICLE TARGETING: COMPOSITIONS, PROCESSES, USES | NANOPROBES INC (US) | 2026-02-19 | — | — | US | claimed |
| EP-4676482-A1 | ONCOLOGY COMBINATION THERAPY AND METHODS OF USE | Beyondspring Pharmaceuticals, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| US-20250375440-A1 | COMPOSITION AND METHOD OF TREATING CANCER ASSOCIATED WITH EGFR MUTATION | BEYONDSPRING PHARMACEUTICALS INC (US) | 2025-12-11 | — | — | US | claimed |
| EP-3801524-B1 | COMPOSITION AND METHOD OF TREATING CANCER ASSOCIATED WITH EGFR MUTATION | BEYONDSPRING PHARMACEUTICALS INC (US) | 2025-11-05 | — | — | EP | claimed |
| US-12458638-B2 | Method of stimulating neutrophil survival and reducing neutropenia | BEYONDSPRING PHARMACEUTICALS, INC. (US) | 2025-11-04 | — | — | US | claimed |
| US-12433886-B2 | Composition and method for reducing neutropenia | BEYONDSPRING PHARMACEUTICALS, INC. (US) | 2025-10-07 | — | — | US | claimed |
| EP-3973963-A1 | QUINOLINE DERIVATIVES FOR TREATMENT OF HEAD AND NECK CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3967310-A1 | QUINOLINE DERIVATIVE USED FOR SOFT TISSUE SARCOMA COMBINATION THERAPY | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-03-16 | — | — | EP | claimed |
| EP-3334726-B1 | PLINABULIN COMPOSITIONS | BEYONDSPRING PHARMACEUTICALS INC (US) | 2022-03-16 | — | — | EP | claimed |
| EP-3957631-A1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| US-11254657-B2 | Plinabulin compositions | BEYONDSPRING PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | claimed |
| US-11229642-B2 | Composition and method for reducing neutropenia | BEYONDSPRING PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | claimed |
| US-20210002259-A1 | POLYCRYSTALLINE FORM OF DEHYDROPHENYLAHISTIN-LIKE COMPOUND, AND MANUFACTURING AND PURIFICATION METHOD AND APPLICATION THEREOF | SHENZHEN HUAHONG MARINE BIOMEDICINE CO., LTD (CN) | 2021-01-07 | — | — | US | claimed |
| CN-107011322-B | Preparation and purification method of dehydrophenylahistine compound | 青岛海洋生物医药研究院股份有限公司 | 2020-02-18 | — | — | CN | claimed |
| EP-3498702-A1 | POLYCRYSTALLINE FORM OF DEHYDROPHENYLAHISTIN-LIKE COMPOUND, AND MANUFACTURING AND PURIFICATION METHOD AND APPLICATION THEREOF. | Marine Biomedical Research Institute Of Qingdao Co., Ltd. (CN) | 2019-06-19 | — | — | EP | claimed |
| US-20190177302-A1 | POLYCRYSTALLINE FORM OF DEHYDROPHENYLAHISTIN-LIKE COMPOUND, AND MANUFACTURING AND PURIFICATION METHOD AND APPLICATION THEREOF | SHENZHEN HUAHONG MARINE BIOMEDICINE CO., LTD (CN) | 2019-06-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048022-A1 | ENDOTHELIAL DAMAGE AND NANOPARTICLE TARGETING: COMPOSITIONS, PROCESSES, USES | VEGFA, FLT1, FLT4 | TUBB4A 948/4885TUBB 1057/4885TUBA3C 1017/4885 |
| US-20260130851-A1 | PLINABULIN MICELLE COMPOSITION AND PREPARATION METHOD THEREFOR | MCL1, LIPG, MTTP | TUBB4A 109/4885TUBB 36/4885TUBA3C 70/4885 |
| US-20210002259-A1 | POLYCRYSTALLINE FORM OF DEHYDROPHENYLAHISTIN-LIKE COMPOUND, AND MANUFACTURING AND PURIFICATION METHOD AND APPLICATION THEREOF | DHPS, HDHD5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TUBB4A 2007/4885TUBB 2938/4885TUBA3C 1498/4885 |
| US-20190177302-A1 | POLYCRYSTALLINE FORM OF DEHYDROPHENYLAHISTIN-LIKE COMPOUND, AND MANUFACTURING AND PURIFICATION METHOD AND APPLICATION THEREOF | DHPS, HDHD5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TUBB4A 2116/4885TUBB 2938/4885TUBA3C 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.